tetano
Editor, Senior Moderator
J Clin Invest
. 2022 Jan 21;e156083.
doi: 10.1172/JCI156083. Online ahead of print.
CD4+ T-cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses
Bezawit A Woldemeskel[SUP] 1 [/SUP], Arbor G Dykema[SUP] 2 [/SUP], Caroline Garliss[SUP] 1 [/SUP], Saphira Cherfils[SUP] 3 [/SUP], Kellie N Smith[SUP] 4 [/SUP], Joel N Blankson[SUP] 1 [/SUP]
Affiliations
Abstract
Recent studies have shown that vaccinated individuals harbor T cells that can cross-recognize SARS-CoV-2 and endemic human common cold coronaviruses (HCoVs). However, it is still unknown whether CD4+ T cells from vaccinated individuals recognize peptides from bat coronaviruses that may have the potential of causing future pandemics. In this study, we identified a SARS-CoV-2 spike protein epitope (S815-827) that is conserved in coronaviruses from different genera and subgenera including SARS-CoV, MERS-CoV, multiple bat coronaviruses and a feline coronavirus. Our results showed that S815-827 is recognized by 42% of vaccinated participants in our study who received the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) COVID-19 vaccines. Using T cell expansion and T cell receptor sequencing assays, we demonstrated that S815-827-reactive CD4+ T cells from the majority of responders cross-recognize homologous peptides from at least 6 other diverse coronaviruses. Our results support the hypothesis that the current mRNA vaccines elicit T cell responses that can cross-recognize bat coronaviruses, and thus might induce some protection against potential zoonotic outbreaks. Furthermore, our data provide important insights that inform the development of T cell-based pan-coronavirus vaccine strategies.
Keywords: Adaptive immunity; COVID-19.
. 2022 Jan 21;e156083.
doi: 10.1172/JCI156083. Online ahead of print.
CD4+ T-cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses
Bezawit A Woldemeskel[SUP] 1 [/SUP], Arbor G Dykema[SUP] 2 [/SUP], Caroline Garliss[SUP] 1 [/SUP], Saphira Cherfils[SUP] 3 [/SUP], Kellie N Smith[SUP] 4 [/SUP], Joel N Blankson[SUP] 1 [/SUP]
Affiliations
- PMID: 35061630
- DOI: 10.1172/JCI156083
Abstract
Recent studies have shown that vaccinated individuals harbor T cells that can cross-recognize SARS-CoV-2 and endemic human common cold coronaviruses (HCoVs). However, it is still unknown whether CD4+ T cells from vaccinated individuals recognize peptides from bat coronaviruses that may have the potential of causing future pandemics. In this study, we identified a SARS-CoV-2 spike protein epitope (S815-827) that is conserved in coronaviruses from different genera and subgenera including SARS-CoV, MERS-CoV, multiple bat coronaviruses and a feline coronavirus. Our results showed that S815-827 is recognized by 42% of vaccinated participants in our study who received the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) COVID-19 vaccines. Using T cell expansion and T cell receptor sequencing assays, we demonstrated that S815-827-reactive CD4+ T cells from the majority of responders cross-recognize homologous peptides from at least 6 other diverse coronaviruses. Our results support the hypothesis that the current mRNA vaccines elicit T cell responses that can cross-recognize bat coronaviruses, and thus might induce some protection against potential zoonotic outbreaks. Furthermore, our data provide important insights that inform the development of T cell-based pan-coronavirus vaccine strategies.
Keywords: Adaptive immunity; COVID-19.